CAR-T therapy for EGFR/B7H3-positive lung and triple-negative breast cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) must sign an ethics-approved consent form before any screening tests.
- You have advanced lung cancer or triple-negative breast cancer confirmed by lab tests.
- Your tumor must test positive for EGFR or B7H3 using an approved stain test within 3 months.
- Your scans must show at least one measurable tumor spot, and your doctor expects you to live at least 12 weeks.
- Your health status must be fairly strong (ECOG 0–1) and major organs must be working well based on blood tests and heart scan (LVEF at least 50%).
- You must be able to use birth control for a long period after the infusion (and for men, contraception is also required).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Hear when a new EGFR/ B7H3-positive Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.